Crescent Biopharma's total assets for Q1 2026 were $199.13M, a decrease of -17.13% from the previous quarter. CBIO total liabilities were $15.28M for the fiscal quarter, a -59.01% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.